Compare Shell PLC (SHEL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs BIO-TECHNE Corp — how do they compare? Shell PLC trades at $95.46 (market cap $271.34B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Shell PLC is far larger — about 23.9× BIO-TECHNE Corp's market cap, and Shell PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals.
| SHEL | TECH | |
|---|---|---|
Market Cap | $271.34B | $11.34B |
Sector | Energy | Health |
52-Week High | $95.60 | $72.48 |
52-Week Low | $70.31 | $43.31 |
Enterprise Value | $313.04B | $11.36B |
Dividend Yield | 3.28% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $95.32, up 2.55% with strong bullish momentum as crude oil prices rally. The stock shows robust fundamentals with a P/E of 10.54 and net income margin of 8.76%, while recent Q2 2026 earnings beat expectations. Technical indicators signal bullish sentiment with the price near resistance at $96. Recent acquisitions including ARC Resources and strategic partnerships with BP expand Shell's deepwater footprint, driving growth prospects.
Outlook remains positive with analyst consensus price target of $101 (6% upside), supported by 61.5% buy ratings. Key risks include oil price volatility and geopolitical tensions, but strong cash flow generation and strategic expansions position SHEL for sustained growth. The current valuation appears attractive relative to earnings potential.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
